DRUG REPOSITION OF NON-CANCER DRUGS FOR CANCER TREATMENTS VIA PHARMACOVIGILANCE APPROACH - REPURPOSING DRUGS IN ONCOLOGY

  • Mrugank Bhaskarkumar Parmar PhD Research Scholar, Department of Pharmacology, Institute of Pharmacy, Nirma University, Ahmedabad - 382481, Gujarat, India
  • Shital Panchal Assistant Professor, Department of Pharmacology, Institute of Pharmacy, Nirma University, Ahmedabad - 382481, Gujarat, India

Abstract

This study for drug repositioning has been performed for the drugs which are in the market since more than a decade and they are approved with their well-established efficacy and safety in human being. Objective of this study was to reposition the existing non-cancer drug therapy for cancer treatment, which is having well characterized pharmacologic profile with more efficacy and least toxicity as anti-neoplastic agent. We have retrieved the source data from FDA Adverse Event Reporting System (FAERS) for the last 13 years covering duration from 2004 to 2016 and analysed those using pharmacovigilance approach ‘a proposed future novel pharmaceutical tool for drug reposition’. Signal management activity was performed for statistical analysis. Result of statistical analysis derived that propranolol; metformin; pioglitazone; dabigatran and nitroglycerin are the existing non-cancer drugs which deserved for their direct / indirect reposition for cancer treatment and anti-neoplastic activity. Further studies retrieving the source data from other regulatory database (e.g. Eudravigilance of EMA and VigiFlow of WHO) and post-marketing surveillance study with the same objective may adjuvant our results for the reposition of existing drugs by pharmacovigilance approach.

Keywords: drug reposition, anti-diabetic therapy, cardiovascular therapy, anti-cancer therapy, pharmacovigilance

References

Adams CP, Brantner VV. Estimating the cost of new drug development: is it really 802 million dollars? Health Aff (Millwood) 2006;25(2):420–428.

Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol. 2008;4:682–690.

Boolell M, Allen MJ, Ballard SA, Gepi-Attee S, Muirhead GJ, Naylor AM. et al. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res. 1996;8:47-52.

Ashburn TT, Thor KB: Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 2004, 3:673-683.

Tobinick EL: The value of drug repositioning in the current pharmaceutical market. Drug News Perspect 2009, 22:119-125.

Li X, Song D, Leng SX. Link between type 2 diabetes and Alzheimer's disease: from epidemiology to mechanism and treatment. ClinInterv Aging. 2015 Mar 10;10:549-60.

Grill JD, Cummings JL. Novel targets for Alzheimer’s disease treatment. Expert review of neurotherapeutics. 2010;10(5):711-728.

Yarchoan M, Arnold SE. Repurposing diabetes drugs for brain insulin resistance in Alzheimer disease. Diabetes. 2014 Jul;63(7):2253-61.

Wang BW1, Hok V, Della-Chiesa A, Callaghan C, Barlow S, TsanovM et. al. Rosiglitazone enhances learning, place cell activity, and synaptic plasticity in middle-aged rats. Neurobiol Aging. 2012 Apr;33(4):835.e13-30.

Giles TD, Sander GE. Effects of thiazolidinediones on blood pressure. CurrHypertens Rep. 2007 Aug;9(4):332-337.

Umrani DN, Banday AA, Hussain T, Lokhandwala MF. Rosiglitazone treatment restores renal dopamine receptor function in obese Zucker rats. Hypertension. 2002 Dec;40(6):880-885.

Negro R, Mangieri T, Dazzi D, Pezzarossa A, Hassan H. Rosiglitazone effects on blood pressure and metabolic parameters in nondipper diabetic patients. Diabetes Res ClinPract. 2005 Oct;70(1):20 25.

Sarafidis PA, Nilsson PM. The effects of thiazolidinediones on blood pressure levels - a systematic review. Blood Press. 2006;15(3):135-50.

Hussain T, Lokhandwala MF. Renal dopamine receptor function in hypertension. Hypertension. 1998 Aug;32(2):187-197.

Eudravigilance Expert Working Group. The use of statistical signal detection methods in the Eudravigilance data analysis system. London, 16 November 2006. Doc. Ref. EMEA/106464/2006

Hofman A, Ott A, Breteler MM, et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer’s disease in the Rotterdam Study. Lancet 1997;349:151–154.

Kloppenborg RP, van den Berg E, Kappelle LJ, Biessels GJ. Diabetes and other vascular risk factors for dementia: which factor matters most? A systematic review. Eur J Pharmacol 2008;585:97–108.

Watson G, Cholerton BA, Reger MA, et al. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatry. 2005;13(11):950–958.

Sarafidis PA, Lasaridis AN: Actions of peroxisome proliferator-activated receptors-gamma agonists explaining a possible blood pressure-lowering effect. Am J Hypertens 2006, 19:646–653.

Beck-Nielsen H, Hanefeld M, Komajda M, Dargie H, Curtis P, Zambanini A, et al. Randomized controlled trial of the effect of rosiglitazone in combination therapy on ambulatory blood pressure in people with type 2 diabetes mellitus followed for 12 months [Abstract]. Diabetologia. 2005;48Suppl 1:A279.

Ruilope LM, Bakris GL, McMorn SO, Weston WM, Huang C, Heise MA, et al. Rosiglitazone added to metformin reduces urinary albumin/creatinine ratio and ambulatory blood pressure in subjects with microalbumi- nuria and type 2 diabetes [Abstract]. Diabetologia. 2005;48Suppl 1:A283.

Cook NR, Cohen J, Hebert PR, et al.: Implications of small reductions in diastolic blood pressure for primary prevention. Arch Intern Med 1995, 155:701–709.

Lewington S, Clarke R, Qizilbash N, et al., Prospective Studies Collaboration: Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002, 360:1903–1913.

FDA Drug Safety Communication. FDA requires removal of some prescribing and dispensing restrictions for rosiglitazone-containing diabetes medicines. 2015 Dec 16. Available at http://www.fda.gov/Drugs/DrugSafety/ucm376389.htm

E Pasquier, J Street, C Pouchy et al. β-blockers increase response to chemotherapy via direct antitumour and anti-angiogenic mechanisms in neuroblastoma. British Journal of Cancer (2013) 108, 2485–2494.

Pantziarka P, Bouche G, Sukhatme V, Meheus L, Rooman I, Sukhatme VP. Repurposing Drugs in Oncology (ReDO)-Propranolol as an anti-cancer agent. Ecancermedicalscience. 2016 Oct 12;10:680.

Leone A, Di Gennaro E, Bruzzese F, Avallone A, Budillon A. New perspective for an old antidiabetic drug: metformin as anticancer agent. Cancer Treat Res. 2014;159:355-76.

Nevadunsky NS, Van Arsdale A, Strickler HD et. al. Metformin use and endometrial cancer survival. GynecolOncol. 2014 Jan;132(1):236-40.

Galli A, Mello T, Ceni E, Surrenti E, Surrenti C. The potential of antidiabetic thiazolidinediones for anticancer therapy. Expert Opin. Invest. Drugs, 2006, 15(9), 1039-1049.

Ceni E, Mello, T, Tarocchi M, Crabb D.W, Caldini, A. Invernizzi, P.; Surrenti, C.; Milani, S.; Galli, A. Antidiabeticthiazolidinediones induce ductal differentiation but not apoptosis in pancreatic cancer cells. W. J. Gastroenterol., 2005, 11(8), 1122-1130.

Tontonoz, P.; Singer, S.; Forman, B.M. et al. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. Proc. Natl. Acad. Sci. USA, 1997, 94(1), 237-241.

Elstner E, Muller C, Koshizuka K et al. Ligands for peroxisome proliferator-activated receptor gamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc. Natl. Acad. Sci. USA, 1998, 95(15), 8806-8811.

Kim S, Lee J.J, Heo D.S. PPAR gamma ligands induce growth inhibition and apoptosis through p63 and p73 in hum an ovarian cancer cells. Biochem. Biophys. Res. Comm., 2011, 406(3), 389-395.

Weng R, Chen Y, Pinzone J, Ringel D, Chen S. Beyond peroxisome proliferator-activated receptor gamma signaling: the multi-facets of the antitumor effect of thiazolidinediones. Endocr-Relat. Cancer, 2006, 13(2), 401-413.

Galli A, Ceni E, Crabb W. et al. Antidiabetic thiazolidinediones inhibit invasiveness of pancreatic cancer cells via PPAR gamma independent mechanisms. Gut, 2004, 53(11), 1688-1697.

Liu J, Lu L, Huang W et al. Peroxisome proliferator activated receptor-gamma ligands induced cell growth inhibition and its influence on matrix metalloproteinase activity in human myeloid leukemia cells. Cancer Chemother. Pharmacol., 2005, 56(4), 400-408.

Omar A, Salama A, Arafa A, Weng R. Antitumor effects of energy restriction-mimetic agents: thiazolidinediones. Biol. Chem., 2013, 394(7), 865-870.

Wei O, Kulp K, Chen S. Energy restriction as an antitumor target of thiazolidinediones. J. Biol. Chem., 2010, 285(13), 9780-9791.

DeFeo K, Hayes C, Chernick M, Ryn JV, Gilmour SK. Use of Dabigatran etexilate to reduce breast cancer progression. Cancer BiolTher. 2010 Nov 15;10(10):1001-8.

Lal I, Dittus K, Holmes CE. Platelets, coagulation and fibrinolysis in breast cancer progression. Breast Cancer Res. 2013;15(4):207.

Vidula S, Gauthier B, Lydie M, Vikas S, Pan P. Repurposing Drugs in Oncology (ReDO)--nitroglycerin as an anti-cancer agent ecancer. 2015;9:568.

Gilbert J, Henske P, Singh A. Rebuilding big pharma's business model. In vivo.2003;21:73–80.

Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients.BMJ. 2005 Jun 4;330(7503):1304-5.

Currie CJ, Poole CD, Jenkins-Jones S, Gale EA, Johnson JA, Morgan CL. Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival. Diabetes Care. 2012 Feb;35(2):299-304.

Lega IC, Austin PC, Gruneir A, Goodwin PJ, Rochon PA, Lipscombe LL. Association between metformin therapy and mortality after breast cancer: a population-based study. Diabetes Care. 2013 Oct;36(10):3018-26.

Landman GW, Kleefstra N, van Hateren KJ, Groenier KH, Gans RO, Bilo HJ. Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care. 2010 Feb;33(2):322-6.

Eikawa S, Nishida M, Mizukami S, YamazakiC, Nakayama E, Udono H. Immune-mediated antitumor effect by type 2 diabetes drug, metformin. PNAS 2015 Jan 26;112(6):1809-1814.

Li W, Wang QL, Liu X et al. Combined use of vitamin D3 and metformin exhibits synergistic chemopreventive effects on colorectal neoplasia in rats and mice. Cancer Prev Res (Phila). 2015 Feb;8(2):139-48.

Prost S, Relouzat F, Spentchian M, Ouzegdouh Y, Saliba J, Massonnet G, et al. Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists. Nature. 2015;525:380-3.

Takahashi H, Hosono K, Uchiyama T, et al. PPAR ligand as a promising candidate for colorectal cancer chemoprevention: a pilot study. PPAR Res 2010 Aug 2.

Niho N, Takahashi M, Shoji Y, Takeuchi Y, Matsubara S, Sugimura T, Wakabayashi K. Dose-dependent suppression of hyperlipidemia and intestinal polyp formation in Min mice by pioglitazone, a PPAR gamma ligand. Cancer Sci. 2003 Nov;94(11):960-4.

Shimada T, Kojima K, Yoshiura K, Hiraishi H, Terano A. Characteristics of the peroxisome proliferator activated receptor gamma (PPARgamma) ligand induced apoptosis in colon cancer cells. Gut. 2002 May;50(5):658-64.

Shen D, Deng C, Zhang M. Peroxisome proliferator-activated receptor gamma agonists inhibit the proliferation and invasion of human colon cancer cells. Postgrad Med J. 2007 Jun;83(980):414-9.

Rumi MA, Sato H, Ishihara S, Ortega C, Kadowaki Y, Kinoshita Y. Growth inhibition of esophageal squamous carcinoma cells by peroxisome proliferator-activated receptor-gamma ligands. J Lab Clin Med. 2002 Jul;140(1):17-26.

Eibl G, Wente MN, Reber HA, Hines OJ. Peroxisome proliferator-activated receptor gamma induces pancreatic cancer cell apoptosis. BiochemBiophys Res Commun. 2001 Sep 21;287(2):522-9.

Chang PY, Huang WY, Lin CL, Huang TC, Wu YY, Chen JH, Kao CH. Propranolol Reduces Cancer Risk: A Population-Based Cohort Study. Medicine (Baltimore). 2015 Jul;94(27):e1097.

Barron TI, Connolly RM, Sharp L, Bennett K, Visvanathan K. Beta blockers and breast cancer mortality: a population- based study. J ClinOncol. 2011 Jul 1;29(19):2635-44.

Pan Pantziarka, Gauthier Bouche, VidulaSukhatme, LydieMeheus, IlseRooman, Vikas P Sukhatme. Repurposing Drugs in Oncology (ReDO)—Propranolol as an anti-cancer agent. ecancermedicalscience, 2016.

DeFeo K, Hayes C, Chernick M, Ryn JV, Gilmour SK. Use of Dabigatran etexilate to reduce breast cancer progression. Cancer BiolTher. 2010 Nov 15;10(10):1001-8.

Lal I, Dittus K, Holmes CE. Platelets, coagulation and fibrinolysis in breast cancer progression. Breast Cancer Res. 2013;15(4):207.

Yasuda H, Nakayama K, Watanabe M et. al. Nitroglycerin treatment may enhance chemosensitivity to docetaxel and carboplatin in patients with lung adenocarcinoma. Clin Cancer Res. 2006 Nov 15;12(22):6748-57.

Vidula S, Gauthier B, Lydie M, Vikas S and Pan P. Repurposing Drugs in Oncology (ReDO)--nitroglycerin as an anti-cancer agent. ecancer 9.568;2015.
Statistics
7 Views | 21 Downloads
How to Cite
Parmar, M., and S. Panchal. “DRUG REPOSITION OF NON-CANCER DRUGS FOR CANCER TREATMENTS VIA PHARMACOVIGILANCE APPROACH - REPURPOSING DRUGS IN ONCOLOGY”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 12, no. 2, Jan. 2019, pp. 310-4, https://innovareacademics.in/journals/index.php/ajpcr/article/view/29523.
Section
Original Article(s)